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Abstract
NRP-2 is a high-affinity kinase-deficient receptor for ligands belonging to the class 3 semaphorin and vascularendothelial growth
factor families. NRP-2 has been detected on the surface of several types of human cancer cells, but its expression and function in
gastrointestinal (GI) cancer cells remains to be determined. We sought to determine the function of NRP-2 in mediating
downstream signals regulating the growth and survival of human gastrointestinal cancer cells. In human gastric cancer
specimens, NRP-2 expression was detected in tumor tissues but not in adjacent normal mucosa. In CNDT 2.5 cells, shRNA
mediated knockdown NRP-2 expression led to decreased migration and invasion in vitro (p,0.01). Focused gene-array analysis
demonstrated that loss of NRP-2 reduced the expression of a critical metastasis mediator gene, S100A4. Steady-state levels and
function of b-catenin, a known regulator of S100A4, were also decreased in the shNRP-2 clones. Furthermore, knockdown of NRP-
2s e n s i t i z e dC N D T2 . 5c e l l sin vitro to5FU toxicity. This effect was associated with activation of caspases 3 and 7, cleavageof PARP,
and downregulation of Bcl-2.In vivo growth of CNDT 2.5 cells in the livers of nude mice was significantly decreased in the shNRP-2
group (p,0.05). Intraperitoneal administration of NRP-2 siRNA-DOPC decreased the tumor burden in mice(p=0.01). Collectively,
our results demonstrate that tumor cell–derived NRP-2 mediates critical survival signaling in gastrointestinal cancer cells.
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Introduction
Neuropilin-2 (NRP-2) is a transmembrane glycoprotein that was
originally described as a receptor for the axon guidance mediators,
the semaphorins [1]. Subsequently, it was found to be expressed by
venous and lymphatic endothelial cells and identified as a
coreceptor for members of the vascular endothelial growth factor
(VEGF) family [2], suggesting a role in angiogenesis and
lymphangiogenesis [3]. NRP-2 expression has been reported on
tumor cells in lung cancer [4,5], neuroblastoma [6], pancreatic
cancer [7], osteosarcoma [8], and bladder cancer [9]. However, the
function of the NRP-2 on the tumor cell membrane in human
cancers, including those of gastrointestinal (GI) neuroendocrine and
gastricorigin, remains largely undefined. Previously,we haveshown
that NRP-2 is expressed on colon and pancreatic cancer cells and
that its expression is involved in promoting tumor growth [10,11].
The purpose of the present study was to determine the function of
NRP-2 in mediating downstream signals regulating the growth and
survival of human gastrointestinal cancer cells. We found that NRP-
2 was overexpressed in human gastric cancer specimens and in
gastric and carcinoid cells in vitro. We elucidated the role of NRP-2
in the cell lines with the highest NRP-2 expression. We found that
loss of NRP-2 reduced the steady-state levels and function of b-
catenin in these cells. NRP-2 knockdown led to decrease in the
expression of S100A4 and decreased migration and invasion of the
cells in vitro. Furthermore, knockdown of NRP-2 sensitized CNDT
2.5 cells in vitro to 5FU toxicity. These results indicate that NRP-2
mediates critical oncogenic functions in GI cancer cells and that
inhibition of its expression and activity could be exploited for
therapeutic benefit in patients with metastatic disease.
Results
Expression of NRP-2 in human gastric cancer tissue and
cell lines
We first assessed the expression of NRP-2 protein in paraffin-
embedded tissues of human gastric cancer and adjacent normal
mucosa by immunoperoxidase staining. In representative gastric
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e23208cancer specimens, NRP-2 protein was expressed in the gastric
cancer epithelium, but not in normal mucosal epithelium
(Figure 1A). NRP-2 protein (,130 kD) was heterogeneously
expressed across five of the six gastrointestinal cancer cell lines
analyzed by western blotting: AGS, CNDT 2.5, MKN74, NCI-
N87 and KKLS (Figure 1B). CNDT2.5 (a human carcinoid cell
line [12,13]) and NCI-N87 expressed the highest levels of NRP-2
and were therefore used for subsequent knockdown studies. As a
control, preincubation of the NRP-2 antibody with the immuniz-
ing peptide confirmed specificity of the antibody.
Effect of NRP-2 expression on cell proliferation in vitro
To understand the function of NRP-2 in gastrointestinal cancer,
we first examined the effects of NRP-2 silencing on the growth of
the CNDT 2.5 cells in vitro. We chose these cells because they
express high endogenous levels of NRP-2. CDNT 2.5 cells were
Figure 1. Assessment of NRP-2 expression in human gastric cancer tissues and cell lines. (A) Immunohistochemical staining for NRP-2
expression in representative tissue sections (20X) of normal human gastric mucosa and gastric cancer specimens (B) Immunoblot analysis of NRP-2
expression in six human GI cancer cell lines. Vinculin served as an internal loading control. (C) Generation of stable CNDT 2.5 cell lines with NRP-2
knockdown. Immunoblot analysis of NRP-1 and -2 expression in CNDT 2.5 cells transfected with shcntr or shNRP-2 plasmids (shNRP-2 clones; C6 and
C10). Vinculin served as a loading control. (D) MTT assay results. Growth rates were no different between the control cells and NRP-2 knockdown
clones. Bars indicate SEM. (E) Top: Mean number of cells that migrated in a Boyden chamber assay. Bottom: Representative images (10X) of migration
assays. (F) Top: Mean number of cells that invaded in BioCoat Matrigel invasion chamber assay. Bottom: Representative images (10X) of invasion
assays.
doi:10.1371/journal.pone.0023208.g001
Neuropilin-2: Role in Gastrointestinal Cancer
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e23208stably transfected with a shRNA control (shcntr) or shNRP-2
(shNRP-2) plasmid, and two shNRP-2 transfected clones with a
marked decrease in NRP-2 protein expression (C6 and C10,
Figure 1C) were selected. shNRP-2 transfection did not affect the
expression of NRP-1 in these cells, verifying the specificity of the
NRP-2 shRNA. We then used an MTT assay to determine the
effect of NRP-2 knockdown on growth rates of the cells in vitro.
Clones stably transfected with shNRP-2 showed no change in
proliferation rates relative to that of shcntr-transfected cells
(Figure 1D).
Effect of NRP-2 expression on migration and invasion
The effect of NRP-2 RNAi on the motility of CNDT 2.5 cells
was examined using Boyden chamber assays. The number of cells
that migrated to the bottom chamber was significantly lower in
shNRP-2 transfected cells (3765 per field) than in shcntr
transfected cells (140612 per field) (p,0.001; Figure 1E, top).
Conversely, when cells with low endogenous expression of NRP-2
(KKLS) were transiently transfected with a NRP-2 cDNA
expression construct in order to overexpress the protein, cell
migration was significantly increased (data not shown).
Cell invasion was evaluated using the modified Boyden
chamber assay with membranes coated with Matrigel. NRP-2
RNAi significantly inhibited the invasion of CNDT 2.5 cells
(64.4%; p,0.001; Figure 1F, top). However, because invasion of
cells in this assay is also a function of the migratory potential of the
cells, it is difficult to tease out the individual contributions. As such,
given that the differences between the two groups is similar in both
the assays, we cannot rule out the notion that the reduced number
of invading cells may merely reflect decreased migration of
shNRP2 clones.
Effect of NRP-2 knockdown on expression of known
metastatic genes
Since invasion and migration are associated with the metastatic
phenotype, we performed a gene array analysis using a focused
human tumor metastasis microarray that represents 113 genes
known to be involved in metastasis. Suppression of NRP-2 caused
a reduction in the expression level of several metastatic genes
(Figure 2A). Many of the downregulated genes that were
responsive to NRP-2 knockdown are known to be associated with
degradation of the extracellular matrix and are highly expressed
during metastasis. Most notably, we observed that downregulating
NRP-2 caused a significant reduction (.95%) in the expression of
S100A4 (Figure 2A). Because S100A4 was highly responsive to
NRP-2 knockdown, we focused on this gene for further studies.
Western blot analysis confirmed that S100A4 protein expression
was significantly reduced after NRP-2 knockdown (Figure 2B).
Effect of NRP-2 knockdown on expression and
localization of b-catenin
Because S100A4 is a direct transcriptional target of b-catenin,
we examined the expression of b-catenin in the NRP-2 knockdown
cells. Total b-catenin protein expression was significantly lower in
the CNDT 2.5 shNRP-2 cells than in the shcntr cells (Figure 2C).
For further confirmation, shcntr and shNRP-2 clones were fixed
and immunostained with anti-b-catenin antibody (red fluores-
cence). Consistent with the western blot data, total b-catenin levels
were significantly reduced in the NRP-2 knockdown cells
(Figure 2D). For further validation in a second gastric cancer cell
line, NRP-2 was knocked down in NCI-N87 cells, which express a
high endogenous level of NRP-2, by lentivirus-mediated stable
shNRP-2 incorporation. After verification of NRP-2 knockdown
(Figure 2E, Middle panel) in these cells, the b-catenin level was
assessed by western blotting. The total b-catenin level was
significantly reduced in these NRP-2 knockdown cells (Figure 2E,
Top panel).
To determine whether the NRP-2-mediated b-catenin expres-
sion was ligand dependent or ligand independent, b-catenin status
was evaluated by western blot analysis in CNDT 2.5 cells after
treatment with blocking antibodies to NRP-2 (anti-NRP-2
B, which
blocks VEGF-C binding, and pan-anti-NRP, which blocks Sema
binding to both NRP-1 and NRP-2 and also blocks VEGF binding
through steric hindrance); anti-NRP1 antibody served as a control
(all from Genentech, San Francisco, CA). Compared with the
control, there was no difference in the expression of b-catenin in
cells treated with the blocking antibodies, suggesting that the NRP-
2-mediated signaling in these cells is ligand independent (data not
shown).
b-catenin is known to exert its function by translocating from
the cytoplasm into the nucleus, where it binds to transcription
factors such as T cell factor (TCF)/lymphoid enhancer-binding
factor and thereby stimulates the transcription of target genes. We
therefore analyzed the relative abundance of b-catenin protein in
the cytosolic and nuclear compartments in CNDT2.5 shNRP-2
and shcntr cells after cell fractionation. As shown in Figure 2F,
NRP-2 knockdown led to significant reduction in the steady-state
level of b-catenin protein in both the cytosolic and nuclear
fractions of the cells.
Effect of NRP-2 knockdown on function of b-catenin
To determine whether NRP-2 knockdown also affected the
signaling activity of b-catenin, we transfected CNDT 2.5 shcntr
and shNRP-2 cells with the TCF reporter plasmid TOPflash or
the control plasmid FOPflash. TOPflash contains a luciferase
reporter under the control of three copies of the wild-type TCF-
binding element upstream of the thymidine kinase minimal
promoter and is specifically regulated by b-catenin signaling. In
FOPflash, the TCF-binding element is mutated. The luciferase
assay demonstrated that reporter activity was decreased 2-fold in
the shNRP-2 cells compared with activity in the shcntr cells
(Figure 3A).
Effect of NRP-2 knockdown on stability of b-catenin
Intracellular b-catenin protein levels are maintained by a
multiprotein ‘‘destruction complex’’ that contains APC, Axin, and
GSK3b. In an active complex, GSK3b phosphorylates b-catenin,
tagging it for recognition by b-trCP, polyubiquitinylation, and
subsequent degradation by the proteasome complex. We per-
formed inhibitor studies to assess the stability of b-catenin in the
NRP-2 knockdown cells. Treatment with MG132, a proteasome
inhibitor, led to restoration of the total b-catenin protein level in
the NRP-2 knockdown cells to the level in the shcntr cells
(Figure 3B). Furthermore, treatment with MG132 also restored the
total b-catenin protein level in both the cytosolic and nuclear
compartments in the NRP-2 knockdown cells (Figure 3C).
Posttranslational modifications are known to play a critical role
in the regulation of b-catenin turnover, and b-catenin is
sequentially phosphorylated by GSK3b. To investigate whether
GSK3b activation was involved in the downregulation of b-
catenin, we examined the phosphorylation status of GSK3b by use
of an antibody against the Ser-9 phosphorylated form of GSK3b.
Ser-9 phosphorylation has been reported to render GSK3b
inactive. As shown in Figure 3D, Ser-9 phosphorylation of
GSK3b was significantly decreased in the shNRP-2 cells,
indicating that in these cells there were increased levels of active
GSK3b protein, which promotes b-catenin degradation. To
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regulation of b-catenin, the effect of lithium chloride (LiCl), a
known inhibitor of GSK3b activity, was analyzed. LiCl has been
reported to induce the inhibitory Ser-9 phosphorylation of GSK3b
while having no effect on other protein kinases. As shown in
Figure 3E, treatment with LiCl stabilized b-catenin protein in the
shNRP-2 cells in a dose-dependent manner.
Effect of NRP-2 knockdown on chemosensitivity of
gastrointestinal cancer cells in vitro
Given the known role of b-catenin in mediating cell survival, we
hypothesized that a reduced b-catenin level in the NRP-2
knockdown cells would translate into increased chemosensitivity
of these cells. To test this hypothesis, we first performed an in vitro
chemosensitivity assay with 5-fluorouracil (5FU), which is used as
standard therapy for gastrointestinal cancers. Consistent with our
hypothesis, by means of annexin V staining, CNDT 2.5 shNRP-2
cells treated with a clinically relevant dose of 5FU demonstrated a
significantly higher percentage of apoptotic cells than did shcntr
cells (25.5% vs. 12.5%, respectively; p,0.05; Figure 4A).
To confirm the mechanism of 5FU-induced cell death, we
compared the activation of apoptotic mediators in the CNDT 2.5
shcntr and shNRP-2 cells treated with 5FU. The activation of
caspase-3 and -7, the effector caspases in the apoptotic cascade,
and cleavage of the caspase substrate PARP, which exerts
proapoptotic activity, were assessed by immunoblotting using
antibodies that specifically recognize their cleaved products.
Consistent with the increased apoptosis in the 5FU-treated
NRP-2 knockdown cells, we observed a marked increase in the
levels of active caspase-3 and -7 in these cells, but not in the shcntr
Figure 2. Effect of NRP-2 knockdown on expression of known metastatic genes. (A) Autoradiographic image of the array membrane
showing differential expression of metastatic genes in shcntr (left) and shNRP-2 (right) cells. Circled spots indicate the position of the S100A4 gene. (B)
Validation of S100A4 protein expression level in cells by immunoblot analysis. Actin served as a loading control. (C) Reduction of the steady-state
level of b-catenin by NRP-2 knockdown. b-catenin expression in shcntr and shNRP-2 cells was determined by immunoblotting. Vinculin served as a
loading control. (D) Verification of reduced b-catenin expression in shNRP-2 cells by immunofluorescence staining. shcntr and shNRP-2 CNDT 2.5 cells
growing in chamber slides were fixed and immunostained with anti-b-catenin antibody (red). Nuclei were counterstained with DAPI (blue). (E)
Validation of b-catenin reduction in a second NRP-2 knockdown gastric cancer cell line. NCI-N87 gastric cancer cells were infected with lentivirus
containing shcntr or shNRP-2 constructs. Immunoblot analysis showed reduction in b-catenin expression in NCI-N87 NRP-2 knockdown cells. Actin
served as a loading control. (F) b-catenin level in the cytoplasmic (Cyto) and nuclear (Nuc) fractions of shcntr and shNRP-2 cells. HSP90 (cytoplasmic)
and LaminB (nuclear) served as fractionation controls.
doi:10.1371/journal.pone.0023208.g002
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5FU-treated shNRP-2 cells, but not in 5FU-treated shcntr cells
(Figure 4B). Additionally, we observed significant expression of the
antiapoptotic protein Bcl2 in the CNDT 2.5 shcntr cells; Bcl2
expression was absent in the shNRP-2 cells.
Effect of NRP-2 knockdown on in vivo growth of
gastrointestinal cancer cells
To examine the effect of NRP-2 knockdown on the growth of
gastrointestinalcancercells invivo,we injected CNDT 2.5shcntror
shNRP-2 clones in the livers (a common site for gastrointestinal
cancer metastasis) of mice (10 animals per group) and assessed
tumorincidenceandtumorvolume. Allmice were ofapproximately
the same weight when sacrificed. Tumor incidence was significantly
lower in the mice injected with shNRP-2 clones than in the mice
injected with shcntr cells (30% for shNRP-2 C6 and 10% for
shNRP-2 C10 vs. 80% for shcntr; p,0.05, Fishers Exact Test,
Figure 5A). Furthermore, tumors produced by CNDT 2.5shNRP-2
cells were significantly smaller (Mean liver tumor volume of
38624 mm
3 and 14610 mm
3 for the two clones, respectively)
than were tumors produced by control cells (Mean liver tumor
volume of 1,7976880 mm
3;p ,0.05; Figure 5B). The plotted data
includes all the 10 mice in each group, including those that did not
develop any tumor (ie, 7/10 and 9/10 respectively in the two
shNRP2 groups Vs 2/10 in the control group). Representative
image of whole liver with tumor from each group is shown in the
lower panel. The knockdown of NRP2 in the tumors was confirmed
by immunoblot analysis of NRP-2 in liver tumor tissues from mice
injected with CNDT 2.5 shcntr or shNRP-2 C6 cells (Figure 5C).
Effect of in vivo targeting of NRP-2 on growth of
gastrointestinal cancer cells
Next, we examined the effect of in vivo administration of NRP-
2 targeted siRNA using 1,2-dioleoyl-sn-glycero-3-phosphatidyl-
Figure 3. Effect of NRP-2 on b-catenin expression and function. (A) Assessment of TCF reporter activity using the b-catenin-responsive
TOPflash or mutant FOPflash reporters. Luciferase activities were measured after transient transfection of the reporter plasmids into shcntr and
shNRP-2 CNDT 2.5 cells (B) Increased proteasome-mediated degradation of b-catenin in shNRP-2 cells. shcntr and shNRP-2 CNDT 2.5 cells were
treated with 30 mM MG132 or equal volume of DMSO (a solvent for MG132) for 2 hours. Cell lysates were analyzed by immunoblotting using anti-b-
catenin antibody (‘w’, no treatment; ‘Ub’, ubiquitinated b-catenin). (C) Immunoblot analysis showing restoration of b-catenin level in the cytoplasmic
and nuclear fractions after treatment with 30 mM MG132 for 2 hours. (D) Decreased levels of phosphorylated GSK3b in NRP-2 knockdown cells.
Immunoblot analysis of phosphorylated GSK3b (at Ser-9) and GSK3b. (E) Restoration of b-catenin level after blocking GSK3b activity in NRP-2
knockdown cells. shcntr or shNRP-2 CNDT 2.5 knockdown cells were treated with increasing concentrations of LiCl for 24 hours and harvested for
immunoblot analysis to detect b-catenin.
doi:10.1371/journal.pone.0023208.g003
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the growth of gastrointestinal cancer xenografts in mice. CNDT
2.5 cells were grown as s.c. xenografts, and NRP-2 siRNA-DOPC
treatment was started on day 7 in mice with visible tumors
(1561.5 mm
3). Treatment consisted of twice weekly intraperito-
neal injection with 5 mg cntr siRNA-DOPC or NRP-2 siRNA-
DOPC. The average volume of tumors in mice treated with
NRP-2 siRNA-DOPC was less than that for mice treated with
cntr siRNA-DOPC sequences (264.4619.4 mm
3 vs. 751.36
150.6 mm
3, respectively; p=0.01; Figure 6A). Furthermore, mice
treated with NRP-2 siRNA-DOPC exhibited a significant
reduction in tumor mass compared with tumor mass in mice
treated with cntr siRNA-DOPC sequences (160618 mg vs.
4596102 mg, respectively; p,0.05; Figure 6B). Immunohisto-
chemical staining of tumor tissues confirmed that NRP-2
expression was reduced in the tumors from mice treated with
NRP-2 siRNA-DOPC sequences compared with tumors from
mice treated with cntr siRNA-DOPC sequences (Figure 6C).
Discussion
Neuropilin-2 (NRP-2) is traditionally known to function as a
nonsignaling coreceptor for class 3 semaphorins and members of
the VEGF family [1,2]. Although the expression of NRP-2 was
originally thought to be limited to neurons, studies have shown
that NRP-2 is expressed on VSMCs, endothelial cells, and tumor
cells. NRP-2 is reported to interact with VEGFR2 and VEGFR3
and increase survival and migration of vascular and lymphatic
endothelial cells [15]. Recent functional studies by Caunt and
colleagues have shown that blocking NRP-2 in a preclinical lung
metastasis model prevented tumor metastasis by blocking the
formation of tumor-associated lymphatics [16].
The expression of NRP-2 has been detected on tumor cells of
patient samples of many tumor types, including glioblastoma,
neuroblastoma, and melanoma. Our laboratory and others have
shown that tumor cell–derived NRP-2 plays a role in tumor
growth [10,11]. We sought to further elucidate the functional role
of NRP-2 and the signaling mechanisms that mediate the function
Figure 4. Effect of NRP-2 knockdown on chemosensitivity of CNDT 2.5 cells to 5FU treatment and on expression and activation of
apoptotic mediators. (A) Annexin V assay on shcntr and shNRP-2 CNDT 2.5 cells after treatment without or with 5FU for 48 hours. (B) Western blot
analysis of apoptotic markers in cell extracts from shcntr and shNRP-2 CNDT 2.5 cells treated without or with 5FU. Vinculin and actin served as loading
controls.
doi:10.1371/journal.pone.0023208.g004
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We demonstrate in this study that NRP-2 is highly expressed by
tumor cells in gastric carcinoma tissues and by gastrointestinal
cancer cell lines, but it is not detectable by immunohistochemistry
in normal gastric mucosa. The mechanisms by which NRP-2
levels are upregulated in gastrointestinal cancers remain unclear.
Interestingly, Tsukamoto and colleagues [17] found that 40% of
gastric cancer patients analyzed had a gain at 2q33 (the region in
which the NRP-2 gene is located) by array comparative genomic
hybridization (CGH) analysis, suggesting copy number aberration
(CNA) of this region.
We utilized a shRNA-mediated RNA interference approach to
suppress NRP-2 expression in gastric cancer cells to investigate the
resulting phenotypic changes, including proliferative, migratory,
and invasive activities. Knockdown of NRP-2 did not affect the
proliferation of the CNDT 2.5 cells in vitro; however, loss of NRP-
2 reduced the growth of tumor xenografts in vivo. The discrepancy
between in vitro and in vivo growth inhibition may be due to NRP-2-
mediated responses from cells in the tumor microenvironment at
the tumor site in vivo that are not appreciable in an in vitro system.
In vitro studies further demonstrated that there was a marked
Figure 5. Effect of NRP-2 on in vivo growth of GI cancer cells.
(A) Decreased tumor incidence and mean tumor volume after NRP-2
knockdown. Tumor incidence (10 mice) after liver injection with CNDT
2.5 shcntr cells or one of two shNRP-2 clones. (B) Top: Final liver tumor
volumes in mice injected with shcntr and shNRP-2 clones. Bottom:
Representative images of tumors. (C) Immunoblot analysis of NRP-2 in
tumors from mice injected with CNDT 2.5 shcntr or shNRP-2 C6 cells
[‘T1’; Tumor #1; ‘T2’; Tumor #2]. b-Actin served as a loading control.
doi:10.1371/journal.pone.0023208.g005
Figure 6. Decreased s.c. growth of CNDT 2.5 cells after systemic
administration of DOPC liposome-conjugated siNRP-2. (A)
Tumor volumes after administration of sicntr and siNRP-2 liposomes.
Nude mice (7 per group) were s.c. injected with 1610
6 CNDT 2.5 cells.
Mice with visible tumors were stratified and treated with 5 mgo f
liposome-conjugated siRNA (i.p. injections) twice weekly. NRP-2-siRNA
DOPC-treatment led to a significant decrease in tumor growth
compared with cntr siRNA DOPC-treatment (264.4 mm
3 vs.
751.3 mm
3, respectively; *p=0.01). (B) Top: At the end of the
experiment, s.c. tumors were excised and weighed. Tumor weight
was significantly lower in NRP-2-siRNA-DOPC treated mice (mean,
160 mg) compared to cntr siRNA DOPC-treated mice (mean, 459 mg;
*p=0.01). Bottom: Representative images of tumors (C) Immunoblot
analysis of NRP-2 in tumors from mice treated with cntr-siRNA DOPC or
NRP-2-siRNA DOPC.
doi:10.1371/journal.pone.0023208.g006
Neuropilin-2: Role in Gastrointestinal Cancer
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e23208inhibition of both migration and invasion of the cells. Using
metastasis-associated genes in a cDNA microarray analysis, we
identified S100A4, a key metastasis mediator gene, to be
significantly downregulated after NRP-2 silencing. S100A4 has
been previously linked to metastasis in several experimental
systems [18,19]. Recent studies have shown that S100A4 may also
contribute to cancer progression by enhancing cell survival
functions. Mahon and colleagues [20] have demonstrated that
S100A4 knockdown sensitizes pancreatic cancer cells to gemcita-
bine treatment, in addition to activating caspases and PARP,
resulting in increased apoptosis and cell cycle arrest. We observed
that downregulation of NRP-2 in gastric cancer cells chemosensi-
tized the cells to 5FU treatment. Further studies are needed to
determine whether NRP-2 mediates prosurvival functions in
gastric cancer cells via S100A4.
Further examination of NRP-2-mediated S100A4 regulation
demonstrated that the steady-state levels and function of b-catenin,
a direct transcriptional regulator of S100A4, were compromised in
the NRP-2 knockdown cells. A large body of data supports the
contribution of activation of the b-catenin signaling pathway in the
development and progression of cancers. The activation of Wnt/b-
catenin signaling is found in about 30% of gastric cancers [21]. In a
recent study, Wang and colleagues [22] have proposed b-catenin
stabilization as a mode of action for ATDC-mediated oncogenic
function in pancreatic cancer. Using a transgenic mouse model,
Oshima and colleagues [23] have showed that cooperation of Wnt
signaling and the prostaglandin E2 (PGE2) pathway causes gastric
cancer development. The sustained b-catenin pathway activation
observed in the NCI-N87 cells must be independent of mutations in
the APC and b-catenin genes because this cell line does not harbor
any inherent mutations in either of these genes. The mechanism by
which NRP-2 silencing affects this pathway remains unclear.
One potential limitation of our study is that we analyzed the
growth of NRP-2 knockdown gastric cancer cells as primary
tumors but did not evaluate the metastasis of tumors. Given our
observation that these cells have decreased migration and invasion
after NRP-2 knockdown, the in vivo metastatic potential of these
cells needs be explored in the future. Further studies are also
clearly needed to elucidate the potential mechanism underlying
the attenuation of the b-catenin pathway by NRP-2 silencing. This
remains a major unresolved issue and is the subject of an ongoing
investigation in our laboratory.
NRP-2 is emerging as a novel therapeutic target. Given the role
of NRP-2 in tumor cell migration and invasion, targeting NRP-2
offers a potential novel approach to inhibit the growth and survival
of cancer cells in patients with metastatic disease. Also, because
NRP-2 appears to have roles distinct from that of the VEGF
family of receptors, targeting NRP-2 is unlikely to have the same
result as targeting VEGF. We have found that treatment of
gastrointestinal cancer cells with bevacizumab has no effect on b-
catenin expression (data not shown). Targeting NRP-2 may
therefore complement and extend the antitumor effects of
therapies that target VEGF, such as bevacizumab.
We found that the NRP-2-mediated b-catenin expression
observed in this study is ligand independent. This ligand-indepen-
dent NRP2 signaling is novel however; the mechanism(s) mediating
this phenomenon remains to be understood. At the present time, we
can only speculate on the mechanism(s) involved, based on those
documented for other membrane receptors. (i) It is conceivable that
in tumor cells increased expression of NRP2 on the cell surface
results in ligand-independent activation of NRP2 mediated signaling
through spontaneous NRP2 binding to VEGFR/plexin. (ii)
Alternatively, ligand-independent NRP2 signaling could also be
activated through homo-dimerization (or heterodimerization with
NRP1) as in the case of many other membrane receptors. NRPs are
known to form homo- or hetero-multimers even in the absence of
ligand through the membrane-proximal c domain. (iii) A third
possibility invokes activation via pathway crosstalk with other
membrane receptors, but this raises the question of how the
postulated receptors are activated. In any instance, proteins that
associate with NRP2, including neuropilininteracting protein(NIP)/
synectin, are likely to be key to ligand-independent signaling. Based
ontheligand-independentnatureofNRP2signallingobservedinour
study, a therapeutic approach to inhibit NRP2 biological activity in
gastric cancer would be using RNA interference.
The data in this study support the following model for the
mechanism by which NRP-2 mediates oncogenic functions in
gastrointestinal cancer cells (Figure 7). In gastrointestinal cancer
cells, sustained NRP-2 signaling drives inhibition of GSK3b to
stabilize b-catenin and engage transcriptional programs that
modulate migration, invasion, and survival functions. In summary,
our findings implicate NRP-2 as an important positive regulator of
b-catenin-dependent signaling in gastrointestinal cancer. NRP-2
mediates critical oncogenic functions in gastrointestinal cancer
cells and therefore is a potential therapeutic target for the disease.
Materials and Methods
Human tissue specimens
Formalin-fixed, paraffin-embedded specimens of gastric cancer
tissues and adjacent non-malignant gastric mucosa were obtained
from The University of Texas MD Anderson Cancer Center tissue
bank through a protocol approved by the institutional review
board of The University of Texas MD Anderson Cancer Center,
Houston, TX, USA. The specimens were collected retrospectively
and therefore a waiver was granted by our Institutional Review
Board. Histopathologic confirmation was provided by the MD
Anderson Cancer Center’s Department of Pathology.
Histopathologic preparation and immunohistochemical
staining of tissue specimens
Patient tissue specimens were stained with an anti-NRP-2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as
described previously [10]. As a control, preincubation of the
NRP-2 antibody with the immunizing peptide confirmed speci-
ficity of the antibody.
Cell lines and cell culture conditions
NCI-N87 and AGS cells were obtained from the ATCC
(Manassas, VA). MKN74 cells were a kind gift from Dr. Gary
Schwartz (Memorial Sloan-Kettering Cancer Center, New York,
NY). CNDT 2.5 cells were established previously in our laboratory
from liver metastases of a chemonaı ¨ve patient with a history of
primary ileal carcinoid tumor using an algorithm developed by our
laboratory [12]. KKLS cells were obtained from Dr. Yukuta
Takahashi (Cancer Research Institute, Kanazawa University,
Kanazawa, Japan). ST-1 cells (a gift from Dr. Bradley McIntyre)
were established from a gastric cancer patient at M. D. Anderson
Cancer Center. All cells were maintained in complete DMEM
supplemented with 10% FBS, 2 mM L-glutamine, and 100 units/
ml penicillin and streptomycin (Life Technologies, Grand Island,
NY) at 37uC in a humidified atmosphere containing 5% CO2.
Construction of shRNA targeting NRP-2 and generation
of stable shRNA cell lines
shcntr and shNRP-2 expression plasmids were created as
described previously [10]. Briefly, two pairs of shRNA were
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and introduced into the pSilencer 4.0 vector (Ambion, Austin, TX)
according to the manufacturer’s directions. The negative control
consisted of a pSilencer 4.0 plasmid containing scrambled NRP-2
target sequences (59-agatcggtggcctatagaacg and 59-gatcatcaccttg-
gaccagac). CNDT 2.5 cells were transfected with 0.5 ng of each
shRNA plasmid as previously described [10] and grown in
selective medium containing 850 mg/ml hygromycin B (Roche
Diagnostics, Mannheim, Germany).
MTT analysis of cell proliferation
In vitro proliferation was analyzed with the reducing tetrazo-
lium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay. Briefly, 2,000 cells of each clone were plated
per well onto 96-well microtiter plates in DMEM with 10% FBS.
Assays were performed by adding 20 ml of MTT substrate to each
well for 2 hours, followed by removal of media and the addition of
200 ml DMSO. Spectrometric absorbance was measured on a
microplate reader (Bio-Rad, Hercules, CA) at a wavelength of
570 nm.
In vitro migration and invasion assays
The inhibitory effect of RNAi on migration of CNDT 2.5 cells
in vitro was assayed using modified Boyden chambers (Coster,
Boston, MA). shcntr or shNRP-2 cells (1610
5) were suspended in
500 ml DMEM with 1% FBS and added to the upper chamber.
DMEM (750 ml) with 10% FBS was added to the bottom
chamber. The chambers were incubated for 48 hours at 37uCi n
a humid atmosphere of 5% CO2. After incubation, the upper
surface of the filters was scraped twice with cotton swabs to remove
cells. The filters were fixed and stained with Diff-Quick reagent
(Dade Behring, Newark, DE). For the invasion assay, the
procedure was similar to that for the migration assay except that
a BioCoat Matrigel invasion chamber (Becton Dickinson, Bedford,
MA) was used. All experiments were repeated in triplicate wells,
and the numbers of invading cells in five high-power fields per
filter were counted at x10 magnification.
Nuclear fractionation, preparation of whole-cell lysates
and western blot analyses
Nuclear proteins were extracted using the Nuclear Extract Kit
(Active Motif, Carlsbad, CA) according to the manufacturer’s
instructions. Whole-cell lysates were obtained by incubating cells
in RIPA solution containing protease inhibitors (Roche Diagnos-
tics, Nutley, NJ). Protein concentrations were determined using a
protein assay kit (Bio-Rad, Hercules, CA). Western blotting was
performed with 50 mg of total cellular protein from each cell line.
Proteins were separated on a 10% SDS–PAGE, transferred onto a
PVDF membrane (Amersham Biosciences, Arlington Heights, IL),
and probed with antibodies against NRP-1 and NRP-2 (Santa
Cruz Biotechnology, Santa Cruz, CA); b-catenin (Upstate/
Millipore, Billerica, MA); caspase 3, caspase 7 and PARP and
their cleaved forms (Cell Signaling Technology, Danvers, MA).
Blots were incubated with HRP–conjugated secondary antibodies,
and proteins were visualized using ECL reagent (Amersham
Biosciences, Arlington Heights, IL). Antibodies used in the
blocking experiment included anti-NRP-2
B, pan-anti-NRP, and
anti-NRP1 (all from Genentech, San Francisco, CA).
Figure 7. Hypothetical schema for NRP-2-mediated activation of b-catenin signaling in gastrointestinal cancer cells. Left: In a GI
cancer cell, increased inactive GSK3b inhibits destruction complex function, leading to stabilization of b-catenin that is free to translocate to the
nucleus and activate transcription of target genes. Right: In a GI cancer cell with NRP-2 knockdown, the active destruction complex phosphorylates b-
catenin and targets it for proteasome-mediated degradation, resulting in decreased activation of downstream target genes.
doi:10.1371/journal.pone.0023208.g007
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Total RNA from shcntr and shNRP-2 cells was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was prepared
from 5 mg of total RNA and labeled in a RT reaction with biotin-
16-dUTP (Roche). The labeled cDNA was hybridized to the Oligo
GEArray Human Tumor Metastasis Microarray (Cat #OHS-028;
SABiosciences, Frederick, MD) and developed as per manufac-
turer’s instructions. The results were analyzed by GEArray
Analyzer software (SABiosciences).
Lentiviral stable shRNA cell lines
Lentiviral vectors (Open Biosystems, Huntsville, AL) containing
control or NRP-2 shRNA were generated as per manufacturers
instructions and used to infect NCI-N87 gastric cancer cells.
b-Catenin luciferase reporter assay
CNDT 2.5 cells were transiently transfected with 1 mg of either
TOPflash or FOPflash TCF reporter constructs (Millipore,
Billerica, MA) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA), and luciferase activity was measured 48 hours after
transfection. Luciferase assays were performed with a dual
luciferase assay kit as per the manufacturer’s instructions
(Promega, Madison, WI). TCF activity was calculated in terms
of extent (fold) of change in activity (TOPflash/FOPflash).
Preparation of siRNA-containing liposomes
Liposomes containing cntr and NRP-2 targeted siRNA
sequences were prepared as previously described [10]. Briefly,
DOPC and siRNA were mixed and lyophilized. The lyophilized
preparations were hydrated in PBS at a concentration of 5 mg/
100 ml before in vivo administration. DOPC nanoliposomes were
detremined to have a mean diameter of 30 nM.
In vivo tumor growth studies
Male athymic nude mice (6–8 weeks) were purchased from the
NCI (Frederick, MD) and were maintained under specific
pathogen-free conditions at the M. D. Anderson Cancer Center
Animal Care Facility and their use in these experiments was
approved by the IACUC (#04-07-03032). shcntr, shNRP-2 C6,
and shNRP-2 C10 cells (1610
6 cells per injection in 0.05 ml
HBSS) were injected directly into the liver of each anesthetized
mouse (Ten mice per clone). Mice were sacrificed at 21 days.
Tumor volumes were calculated as [(length) 6(width
2/2)].
For the systemic siRNA delivery experiment, 1610
6 CNDT 2.5
cells (in 0.1 ml HBSS) were injected s.c. into each mouse (right
rear flank). Mice with visible tumors were stratified and
administered cntr-siRNA DOPC or NRP-2-siRNA DOPC
complexes (5 mg siRNA per injection) as a 100 ml bolus i.p. twice
weekly. After 5 treatments, the mice were sacrificed, and tumors
were harvested and analyzed.
Annexin V staining
The percentage of apoptotic cells was assessed using the
Annexin V FITC Apoptosis Detection Kit (BD Pharmingen,
San Diego, CA) according to the manufacturer’s instructions.
Annexin V quantitation was performed using a Coulter EPICS
XL-MCL FAC analyzer (Beckman Coulter, Miami, FL).
Statistical analyses
All data are expressed as mean 6 SE. Statistical analyses were
performed with InStat 2.01 statistical software (GraphPad
Software, San Diego, CA). The differences between groups were
determined by paired Student t-test, Fisher exact test or Mann-
Whitney U tests. p values ,0.05 were considered statistically
significant.
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